Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Fund Details
Upturn AI Summary
Leverage Shares 2X Long BMNR Daily ETF(BMNG)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for BMNG
10/14/2026: BMNG (1-star) is a SELL. SELL for 4 days. Simulated Profits (-17.80%). Updated daily EoD!
Leverage Shares 2X Long BMNR Daily ETF (BMNG) is a specialized product providing 2x the daily performance of BioMarin Pharmaceutical stock through synthetic swap agreements. Its primary strength is providing amplified intraday exposure for active traders, though this comes with high costs and substantial risk due to compounding decay. It is best suited for sophisticated investors looking for tactical short-term positions, not for long-term portfolio holding. Key risks include intense volatility, concentration in a single security, and the structural erosion of value over time. Investors must closely monitor both the underlying stock's performance and market volatility.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
ETF holdings, costs, diversification, valuation, risks, and market conditions provide supporting context about the fund.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Weak fit | This fund is designed for short-term tactical trading rather than long-term growth investment. |
| Momentum investor | Strong fit while signal remains positive | Active momentum traders may use this to amplify gains during strong directional price moves in BMNR. |
| Value investor | Weak fit | Value investors generally avoid the high costs and volatility decay associated with leveraged daily products. |
| Dividend/Income investor | Weak fit | The fund does not provide consistent income and carries risks unsuitable for income-focused portfolios. |
| Low-risk investor | Weak fit | This product carries significant risk due to the 2x leverage factor and volatility, making it inappropriate for low-risk profiles. |
Investor Profile
Ideal Investor Profile
Sophisticated, active traders who monitor the market daily and understand the risks of leveraged decay.
Suitability
This is strictly a tool for active, short-term tactical trading and is unsuitable for long-term passive index followers.
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Volatility | High | The 2x leverage factor doubles the daily volatility compared to the underlying stock. |
| Market risk | High | The fund is highly sensitive to the market performance of a single company, BioMarin. |
| Concentration | High | 100% exposure to a single stock creates extreme concentration risk. |
| Tracking/expense | Medium / high | Daily rebalancing and swap costs can erode value over time due to compounding decay. |
| Liquidity | Medium | Lower trading volume may lead to wider spreads and difficulty executing large orders. |
| Business/sector quality | Medium / high | Performance is entirely dependent on the operational success of one biotech company. |
Risk Analysis
Volatility
Extremely high due to the 2x leverage multiplier applied to daily movements.
Market Risk
Concentrated risk in BioMarin Pharmaceutical (BMNR) exposes investors to idiosyncratic company risks.
What the ETF Owns
| Exposure Type | Exposure | Weight (%) | Retail Investor Read |
|---|---|---|---|
| Single stock | BioMarin Pharmaceutical Inc. (BMNR) — seeks 2x daily return | 100 | This position provides the leveraged exposure to the performance of BioMarin Pharmaceutical as required by the fund's objective. |
Price Behavior
Steep Decline
The stock price has dropped sharply with strong downward pressure.
Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type ETF | Historic Profit -3.31% | Avg. Invested days 12 | Today’s Advisory SELL |
Upturn Advisory Rating  | Upturn Advisory Performance  3.0 | ETF Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/14/2026 |
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.